Metabolic Syndrome (MetS) has been shown as risk and prognostic factors of cancer. MetS affects the prognosis of breast cancer patients differently according to the race, breast cancer type, metabolic component, cancer treatment and concomitant medication. Whether MetS influence the prognosis of the luminal type breast cancer patients has not been confirmed yet. This study aims at analyzing the association between metabolic syndrome and disease-free survival of luminal-type breast cancer patients.
Data from medical record of all non-metastatic breast cancer patients, luminal-type, HER-2 negative, receiving chemotherapy ± radiotherapy and or hormonal therapy, and diagnosed between 2013 – 2018 were extracted and included for this retrospective study. Cases with previous or concomitant malignancy, or which recurrent event is not assessed by imaging or cytology, or incomplete data, or follow up cannot be done were excluded from study. MetS is defined as Modified NCEP ATP III for Asian. Kaplan-Meir Survival analysis were used to estimate cumulative survival time for recurrence based on MetS status of breast cancer patients.
There were 127 non-metastatic, luminal-type breast cancer included for analysis. Median age of subjects was 54-year-old (36-84 years). MetS were found in 47.2% of breast cancer patients with luminal type. Obesity and overweight occured in 40.9%; hypertension in 50.4%; low LDL in 51.2%; hyperglycemia in 56.7%; and increased waist circumference in 56.7%. Relapsed rate was similar between MetS and metabolic normal patients. Eighteen out of 60 luminal-type breast cancer patients with MetS were recurred (30%) as well as 33.3% of breast cancer without MetS. Median disease-free survival in MetS luminal type breast cancer was 84 months while in non MetS was 106 months (95% CI 16,6-151.3; p < 0.62).
In luminal-type breast cancer patients, MetS was not a prognostic factor for relapse. Concomitant medications used for metabolic syndromes, or cancer treatment may obscure the results.
Clinical trial identification
Ethics Committee Approval KE/FK/0670/EC/2018.
Legal entity responsible for the study
Medical And Health Research Ethics Commitee (MHREC) Faculty of Medicine Gadjah Mada University - Dr Sardjito Hospital.
Has not received any funding.
All authors have declared no conflicts of interest.